Aclaris醫療 ACRS 深 滬
等待開盤 10-03 09:30:00 美东时间
1.84
-0.030
-1.60%
華盛通- 最 高1.8974
- 今 開1.87
- 成交量 78.19万股
- 最 低 1.81
- 昨 收 1.87
- 總市值 1.99亿
- 52周最高 5.17
- 市盈率 靜 --
- 換手率 0.72%
- 52周最低 1.05
- 委 比 -22.94%
- 總股本 1.08亿
- 歷史最高 33.88
- 量 比 0.72
- 振 幅 4.67%
- 歷史最低 0.5902
- 每 手 1
- 風險率 0.71%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Aclaris Therapeutics To Host 2025 R&D Day In Midtown, New York On October 14 To Discuss Its Progress In Addressing Therapeutic Gaps In Immuno-Inflammatory Markets
Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that the Company will host it's 2025
09-30 19:14
Aclaris Therapeutics to Host In-Person and Webcast R&D Day, “Patient Focused Innovation: Addressing Gaps in Immuno-Inflammatory Markets”, in New York on October 14, 2025
Aclaris Therapeutics is hosting its 2025 R&D Day on October 14, 2025, in New York. The event will feature presentations by company leadership, Dr. Zuzana Diamant, and Dr. Michael C. Cameron, discussing Aclaris' progress in developing novel treatments for immune-inflammatory diseases. Topics include its innovative discovery platform, ITK inhibition franchise, TSLP franchise, and clinical trial updates. A live Q&A session and webcast will be availa...
09-30 11:00
An Overview of High Tide's Earnings
High Tide (NASDAQ:HITI) is preparing to release its quarterly earnings on Monda...
09-12 22:00
Aclaris Therapeutics' ATI-2138 Phase 2a Trial Results To Be Presented At 2025 EADV Congress In Paris For Moderate-To-Severe Atopic Dermatitis
- Late Breaking Abstract to Present Additional Data from Aclaris' Phase 2a Trial of ATI-2138 in Atopic Dermatitis-WAYNE, Pa., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage
09-09 19:20
Aclaris Therapeutics Announces Late-Breaking Abstract and Oral Presentation On ATI-2138 Phase 2a Results at the 2025 European Academy of Dermatology and Venereology (EADV) Congress
Aclaris Therapeutics, Inc. announced that a late-breaking abstract on its Phase 2a trial of ATI-2138, an investigational oral inhibitor of ITK and JAK3, was selected for presentation at the 2025 EADV Congress in Paris. The presentation will include additional results from the Phase 2a trial in patients with moderate-to-severe atopic dermatitis. ATI-2138, which targets T cell function and IL-2ϒc signaling, has shown potential in preclinical models...
09-09 11:00
Aclaris Therapeutics, Inc.'s (NASDAQ:ACRS) Shares Climb 26% But Its Business Is Yet to Catch Up
尽管已经有了强劲的表现，Aclaris Therapeutics, Inc.（纳斯达克：ACRS）的股票仍在持续上涨，过去三十天上涨了26%。这三十天的表现使年...
08-30 20:17
TSLP：自免领域崛起的“吸金”明星靶点
（来源：药研网） 前言 2025年上半年，阿斯利康财报显示其呼吸与免疫领域重磅产品Tezspire（TSLP单抗）销售额同比增长高达73%，推动公司整体业绩增长...
08-12 07:55
Aclaris Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Aclaris Therapeutics announced positive results from its Phase 2a trial of ITK/JAK3 inhibitor ATI-2138, confirming tolerability and strong efficacy signals in moderate-to-severe atopic dermatitis (AD), validating ITK as a therapeutic target. The company also advanced its anti-TSLP monoclonal antibody Bosakitug into a Phase 2 trial in AD and initiated dosing for its anti-TSLP/IL-4R bispecific antibody ATI-052 in a Phase 1a/1b program. Aclaris repo...
08-07 10:59
盘前异动丨星巴克涨超4%，LendingClub大涨23%，FuboTV涨超9%
7月30日周三，美股三大指数期货在盘前时段小幅走高。今日美国将公布7月ADP就业人数、第二季度实际GDP年化季率初值。美联储FOMC于周四凌晨公布利率决议，鲍威...
07-30 16:24
Aclaris Therapeutics Reveals Top-Line Results from Open-Label Phase 2a Trial of ATI-2138; Primary Endpoint Analysis Confirms Favorable Tolerability Profile Of ATI-2138 Without Certain Risks Associated With Other Agents In The Class; Efficacy Results Show Comparable Outcomes To Approved Therapies With Potential For Improved Tolerability, Supporting Exploration Of Higher Doses In Future Clinical Trials
WAYNE, Pa., July 29, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today
07-30 04:04
